Karyopharm Therapeutics (KPTI) Receivables (2019 - 2025)

Karyopharm Therapeutics has reported Receivables for 7 years, with the latest figure at $26.2 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables fell 14.91% year-over-year to $26.2 million; the trailing twelve-month figure through Dec 2025 stood at $26.2 million (down 14.91% YoY), and the FY2025 full-year result was $26.2 million, down 14.91% from the prior year.
• Receivables for Q4 2025 stood at $26.2 million, down from $31.9 million in the prior quarter.
• The five-year high for Receivables was $47.1 million in Q4 2022, with the low at $17.8 million in Q1 2021.
• Historically, Receivables has averaged $29.5 million across 5 years, with a median of $30.9 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables surged 109.3% — and 2023, when it tumbled 42.74%.
• Karyopharm Therapeutics' Receivables stood at $22.5 million in 2021, then surged by 109.3% to $47.1 million in 2022, then plunged by 42.74% to $27.0 million in 2023, then advanced by 14.11% to $30.8 million in 2024, then fell by 14.91% to $26.2 million in 2025.
• The last three Receivables figures came in at $26.2 million (Q4 2025), $31.9 million (Q3 2025), and $32.9 million (Q2 2025), per Business Quant data.